

# Declaration of interests

*(Please note that high quality of scientific expertise is by nature based on prior experience and that therefore having an interest does not necessarily mean having a conflict of interest)*

Name : **Alexandre Maciuk**

Title: **MR.**

Profession : -

## Current EFSA Involvements

- Member - NDA Panel Experts (2018-2024)
- Member - WG/U/NUTRI/2018/01 - Traditional Foods from Third Countries

## Interests

### I. Financial investments

No interests

### II. Managerial role

No interests

### III. Member of a scientific advisory entity

Period: **01/10/2021 - 01/09/2023**

Organisation: **Agence nationale de sécurité du médicament et des produits de santé**

Impact on annual earnings: **<5%**

*Subject matter:* Working group on pharmacopoeia monographies.

Remit: collection/compilation of data/redaction of monographs about herbal drugs (e.g. quality standards, methods of analysis). No Risk Management duty.

---

Period: **01/09/2012 - 01/07/2018**

Organisation: **Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail**

Impact on annual earnings: **between 5% and 25%**

*Subject matter:* Expert in the CES Nutrition humaine (specialized experts committee in human nutrition) from sept 2012 to July 2015. Remit: risk assessment pertaining to food ingredients. Chair of the working group Nutrivigilance from sept 2012 to July 2018. remit: Remit: collecting and processing adverse effects of dietary supplements, risk assessment pertaining to food ingredients.

## IV. Employment

Period: **01/09/2007 - now**

Organisation: **Université Paris Saclay**

Impact on annual earnings: **>25%**

*Subject matter:* Remit : teaching and research on natural products, pharmacy, chemistry.

## V. Occasional consultancy

Period: **01/02/2020 - 01/02/2022**

Organisation: **JVL Consulting**

Impact on annual earnings: **0%**

*Subject matter:* Participation to the European Commission-supported project on “Organisation and implementation of training activities on EU rules applicable to the authorization and placing on the market of novel foods produced in non-UE countries” (Tender Chafea /2018/BTSF/07). The project is for the EU to promote its standards and measures in the Novel Food sector with its non-EU trade partners. My role as Training co-ordinator.

## VI. Research funding

Period: **01/10/2021 - now**

Organisation: **IRESF (Institut pour la Recherche en Santé Publique) & InCA (Insitut national du cancer)**

*Subject matter:* Public funding of a project on illegal drug checking and risk reduction policy

Does the funding received from the private sector during the two years preceding the submission of the ADol exceeds 25% of the total research budget that is managed by you for the area under concern: **No**

*Additional Info:*

---

Period: **01/01/2018 - now**

Organisation: **L'Agence Nationale de la Recherche**

*Subject matter:* ANR is a public body under the authority of the French Ministry of research. It provides funding for project-based research in all fields of science - for both basic and applied research. Master and doctoral grant for research on the biosynthesis of complex dimers in mushrooms. Budget<5% of the laboratory budget.

Does the funding received from the private sector during the two years preceding the submission of the ADol exceeds 25% of the total research budget that is managed by you for the area under concern: **No**

*Additional Info:*

---

Period: **01/01/2016 - 01/09/2018**

Organisation: **Centre National de la Recherche Scientifique**

*Subject matter:* CNRS is a publicly funded research organization, under the authority of the French Ministry of Research (<http://www.cnrs.fr/en/home/faq.htm>). Travel expenses pertaining to the setup of an international associate laboratory (my lab UMR 8076 BioCIS, Université Paris-Sud and Institute of Chemistry, University of California at Riverside). Topic of the research : screening and design of ligand of DNA structures. Budget<5% of the laboratory budget.

Does the funding received from the private sector during the two years preceding the submission of the ADol exceeds 25% of the total research budget that is managed by you for the area under concern: **No**

*Additional Info:*

---

Period: **01/09/2007 - 01/07/2019**

Organisation: **FNPC, Fédération Nationale des Producteurs de Chanvre**

*Subject matter:* FNPC is a non-profit association functioning on cooperative basis and pertaining to hemp seed production for farmers. Remit of the contract: assistance for selection of hemp varieties, applying analytical expertise to cannabinoid quantification. Income <5% of the lab budget.

Does the funding received from the private sector during the two years preceding the submission of the ADol exceeds 25% of the total research budget that is managed by you for the area under concern: **No**

*Additional Info:*

---

Period: **01/09/2007 - 01/07/2018**

Organisation: **ASP, Agence de Services et de Paiement**

*Subject matter:* ASP is a French public institution. Its mission is to contribute to the implementation of public, national and European policies by supporting public decision-makers <https://www.asp-public.fr/>). Contract for the legal quantification of cannabinoids in French hemp cultures. This contract is granted upon public call. I manage the analytical work, but the budget (<5% of the laboratory budget) is not under my supervision.

Does the funding received from the private sector during the two years preceding the submission of the ADol exceeds 25% of the total research budget that is managed by you for the area under concern: **No**

*Additional Info:*

## VII. Intellectual property rights

Period: **01/07/2009 - now**

Organisation: **Université Paris-Sud**

Impact on annual earnings: **0%**

*Subject matter:* 3 patents (ownership shared with university and several co-authors). Patents without industrial exploitation so far, thus no royalties. Patents pertain to 1) "Procédé de purification de la galanthamine et d'alcaloïdes dérivés par chromatographie de partage centrifuge", (2009) - 2) screening of antimalarial compounds 3) Inhibitors of enzyme for the treatment of Parkinson disease.

## VIII. Other memberships or affiliations

Period: **01/09/2010 - now**

Organisation: **Elsevier, Wiley, Spandidos Publications, MDPI, Taylor & frais, Springer, Georg Thieme Verlag**

Impact on annual earnings: **0%**

*Subject matter:* referee of peer-reviewed journals (no income): Asian Pacific Journal of Tropical Medicine Journal of Chromatography A Journal of Pharmaceutical and Biomedical Analysis Marine Drugs Molecules Phytotherapy Research Planta Medica Phytochemistry Reviews pharmaceutical Biology International Journal of oncology

## IX. Other relevant interest

No interests

---

## User Agreement

I confirm that:

- I think I do not have a conflict of interest with respect to my activity(ies) at EFSA
- ~~I think I have a conflict of interest with respect to my activity(ies) at EFSA~~

Remarks:

I hereby declare that I have read the [EFSA Decision on Competing Interest Management](#) implementing EFSA's Policy on Independence and that the above declaration is truthful and complete.

Doi submitted on: 19-09-2021 - 14:36 (UTC)

Signature: SIGNED

---

## Note regarding the processing of personal data

EFSA processes all Declarations of Interests (Dols) in accordance with Regulation (EU) 2018/1725. DoI processing is necessary in order to safeguard the independence of EFSA and enable the Authority to carry out its mission and comply with its obligations under Regulation (EC) No 178/2002.

The Executive Director of EFSA is the data controller with respect to the handling of Dols.

Concerned individuals have the right to access, rectify, erase and object to the processing of their ADol at any time. Nevertheless, for certain categories of individuals (e.g., experts), it may be a mandatory requirement to submit a DoI to EFSA so as to verify the absence of conflicts of interests and thus protect the independence of EFSA. Concerned individuals will be contacted if EFSA becomes aware of information that is not consistent with the declared interest such as on the occasion of compliance monitoring activities outlined in the relevant [Standard Operating Procedure](#).

Certain ADols shall be made publicly available in accordance with Article 38(1)(d) of Regulation (EC) No 178/2002. Furthermore, ADols may be transferred to bodies in charge of monitoring, auditing or inspection in conformity with EU Law.

The conservation period for ADols per category of data subjects is 10 years from the date of submission of the relevant ADol.

Concerned individuals may direct any queries regarding personal data processing by EFSA to the data protection officer [DataProtectionOfficer@efsa.europa.eu](mailto:DataProtectionOfficer@efsa.europa.eu). They are entitled to submit a complaint at any time to the European Data Protection Supervisor: <http://www.edps.europa.eu>

The legal basis for ADol processing is provided for in Articles 22, 37 and 38 of Regulation (EC) No 178/2002.